ArticleBMC urology2025
CpG dinucleotide methylation of the SPDEF gene as a blood-based epigenetic biomarker for prostate cancer diagnosis.
Article in BMC urology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- SPDEF downregulation promotes tumor aggressiveness and poor prognosis in triple-negative breast cancer.Translational cancer research · 2026Article
- A multi-gene urinary extracellular vesicle mRNA panel as a non-invasive biomarkers for prostate cancer detection.Scientific reports · 2026Article
- Assessing the Tumor Suppressive Impact and Regulatory Mechanisms of SPDEF Expression in Breast Cancer.Cancers · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
backgroundProstate cancer (PCa) is the second most commonly diagnosed malignancy in men and is projected to cause approximately 35,250 deaths in 2024. The utility of total prostate-specific antigen (PSA) testing as a routine screening tool remains controversial due to limited specificity. Therefore, the identification of novel, noninvasive biomarkers is essential for improving early diagnosis. This study aimed to evaluate the methylation status of a specific CpG dinucleotide within the SPDEF (SAM-pointed domain-containing ETS transcription factor) gene promoter in blood leukocytes of PCa patients, using benign prostatic hyperplasia (BPH) samples as a control group.
methodsPeripheral blood samples were collected from 360 men, including 180 diagnosed with PCa and 180 with BPH. A target CpG dinucleotide (cg11346722) in the SPDEF promoter was selected based on analysis of The Cancer Genome Atlas (TCGA) data. Methylation levels were assessed using methylation-sensitive restriction enzyme PCR (MSRE-PCR) and quantitative PCR (qPCR). Associations between methylation and clinical parameters-tumor stage (TS), histological grade, and total PSA levels-were analyzed.
resultsThe mean methylation level at the SPDEF CpG site was significantly lower in PCa patients (hypomethylation: 92 ± 11.76%) compared to BPH controls (15.5 ± 15.12%) (p < 0.0001). Receiver operating characteristic (ROC) curve analysis demonstrated that SPDEF hypomethylation discriminated PCa from BPH with 98.3% sensitivity and 98.3% specificity at a < 55% methylation cutoff. A significant inverse correlation was observed between SPDEF methylation and both tumor stage (TS) and grade, whereas no correlation was found with total PSA levels.
conclusionsHypomethylation of a specific CpG dinucleotide in the SPDEF promoter may serve as a promising noninvasive blood-based biomarker for the early detection and clinical stratification of prostate cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.